Novavax WKN: A2PKMZ ISIN: US6700024010 Kürzel: NVAX Forum: Aktien Thema: Hauptdiskussion

Wünsche allen ein schönes Wochenende! Es steht uns ein äußerst spannenender Monat September bevor. Beste Grüße und bis Dienstag (Montag hat die Börse in den USA zu), Longie

Sehr Interessant! bald 20 Euro wegen dieser Nachricht.

Und von Novavax wieder keine Rede?

https://www.google.com/amp/s/www.cnbc.com/amp/2023/09/01/covid-when-to-wear-masks-as-cases-rise-new-variants-emerge-in-us-.html

Das Teil ist geil zum traden😂

Im Radio läuft schon das die angepasste Auffrischungsimpfung von BIontech/Pfizer ab 18.09. in den Arztpraxen gespritzt wird....

Es brrrrrodelt ordentlich im Nova-Kessel ! Bald fliegt der Deckel!

Ja jetzt wieder das Management und später ist es Manipulation. Ihr seid dermaßen benebelt 🤣

bräuchte mal ein kurzes Statement vom Management , was bei novavax im Hintergrund so läuft.. vielleicht kommende Woche

Jap, sie fällt

geht schon los ..

wird heute wahrscheinlich laufen wie gehabt. shortattacke folgt auf anstieg. aber der kessel wird immer heisser, bis er mal platzt! halten und abwarten

MA200 heute bei 9,50$(Tagesintervall NASDAQ)...akt. 8,43$ ....😁

https://medical.novavax.com/publications-posters-presentations

Highlights • NVX-CoV2373 manufacturing lots are consistently immunogenic and well-tolerated. • NVX-CoV2373 can be used as a first booster dose or a later booster dose. • NVX-CoV2373 is also immunogenic against Omicron BA.1/BA.5 SARS-CoV-2 variants. Abstract Background To combat the SARS-CoV-2 pandemic, multiple vaccines using different manufacturing platforms have been developed, including NVX-CoV2373 (an adjuvanted recombinant protein vaccine). As SARS-CoV-2 variants have emerged, some of which evade vaccine-induced immunity, introduction of vaccine booster doses has become critical. Employing different vaccine types for primary series vaccination and boosting could expand vaccine coverage and access. This study assessed whether NVX-CoV2373 would induce robust responses when used as a booster. Methods The 2019nCoV-307 study was a phase 3, randomized, observer-blinded trial evaluating immunogenicity and safety of NVX-CoV2373 in previously vaccinated adults aged 18–49 years in the United States (NCT05463068). Participants were randomized 1:1:1 to receive one intramuscular injection of NVX-CoV2373 from one of three different manufacturing lots. Immunogenicity was assessed by immunoglobulin G (IgG) and neutralizing antibodies (NAb). These responses were compared for the three lots, and for participants with primary series with or without a prior booster dose of the mRNA-1273, BNT162b2, Ad26.COV2.S, or NVX-CoV2373 COVID-19 vaccines. Results A total of 911 participants were randomized between July 11 and 13, 2022, with 905 being assessed for safety and 848 for immunogenicity. Immunogenicity of NVX-CoV2373 met prespecified equivalence criteria between lots, and the booster dose was well-tolerated. NVX-CoV2373 induced robust IgG and NAb responses when used as a first or later booster dose, regardless of primary series vaccine type. Seroconversion rates were also similar across previous vaccine types. Induced antibodies were strongly reactive, even to the immune-evasive Omicron BA.1 and BA.5 variants. Conclusions NVX-CoV2373 showed consistent immunogenicity between lots, with no new safety signals identified. Use of NVX-CoV2373 as a booster dose (first or later) is supported.